Francesca Di Pressa

Dr. Francesca Di Pressa

University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Orthopaedics & Traumatology: Surgery & Research
Verified
Journal Article
Closed access
RCR. Casadei
R. Casadei
GDG. Drago
G. Drago
FPFrancesca Di Pressa
Francesca Di Pressa
DDD. Donati
D. Donati

30 June 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
FIFederico Iori
Federico Iori
ABAlessio Bruni
Alessio Bruni
SCSalvatore Cozzi
Salvatore Cozzi
PCPatrizia Ciammella
Patrizia Ciammella
FPFrancesca Di Pressa
Francesca Di Pressa
CICinzia Iotti
Cinzia Iotti
Despite the rising evidence in favor of immunotherapy (IT), the treatment of oncological patients affected by so-called “cold tumors” still represents an open issue. Cold tumors are characterized by an immunosuppressive (so-called cold) tumor microenvironment (TME), which favors host immune system suppression, cancer immune-escape, and a worse response to IT. However, the TME is not a static element, but dynamically mutates and can be changed. Radiotherapy (RT) can modulate a cold microenvironment, rendering it better at tumor killing by priming the quiescent host immune system, with a consequent increase in immunotherapy response. The combination of TME radiomodulation and IT could therefore be a strategy for those patients affected by cold tumors, with limited or no response to IT. Thus, this review aims to provide an easy, rapid, and practical overview of how RT could convert the cold TME and why cold tumor radiomodulation could represent an interesting strategy in combination with IT.

29 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ARAlessia Di Rito
Alessia Di Rito
Francesco FioricaFrancesco Fiorica
Francesco Fiorica
RCRoberta Carbonara
Roberta Carbonara
FPFrancesca Di Pressa
Francesca Di Pressa
FBFederica Bertolini
Federica Bertolini
EDELISA D'ANGELO
ELISA D'ANGELO
When presenting with major pathological risk factors, adjuvant radio-chemotherapy for oral cavity cancers (OCC) is recommended, but the addition of chemotherapy to radiotherapy (POCRT) when only minor pathological risk factors are present is controversial. A systematic review following the PICO-PRISMA methodology (PROSPERO registration ID: CRD42021267498) was conducted using the PubMed, Embase, and Cochrane libraries. Studies assessing outcomes of POCRT in patients with solely minor risk factors (perineural invasion or lymph vascular invasion; pN1 single; DOI ≥ 5 mm; close margin < 2–5 mm; node-positive level IV or V; pT3 or pT4; multiple lymph nodes without ENE) were evaluated. A meta-analysis technique with a single-arm study was performed. Radiotherapy was combined with chemotherapy in all studies. One study only included patients treated with POCRT. In the other 12 studies, patients were treated with only PORT (12,883 patients) and with POCRT (10,663 patients). Among the patients treated with POCRT, the pooled 3 year OS rate was 72.9% (95%CI: 65.5–79.2%); the pooled 3 year DFS was 70.9% (95%CI: 48.8–86.2%); and the pooled LRFS was 69.8% (95%CI: 46.1–86.1%). Results are in favor of POCRT in terms of OS but not significant for DFS and LRFS, probably due to the heterogeneity of the included studies and a combination of different prognostic factors.

17 May 2024 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
FPFrancesca Di Pressa
Francesca Di Pressa
FPFabiana Perrone
Fabiana Perrone
ABAnna Benini
Anna Benini
FLFrank Lohr
Frank Lohr
Marcello TiseoMarcello Tiseo
Marcello Tiseo
ABAlessio Bruni
Alessio Bruni
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC). Similarly, the improvement of radiation therapy techniques has permitted to deliver high radiation doses to a limited number of metastatic target lesions (oligopersistent or oligoprogressive), with limited high-dose normal tissue exposure that leads to low severe toxicity rates. The aim of this narrative review was to provide an overview of the currently established definition of oligometastatic and oligoprogressive disease, to define first line and subsequent lines targeted therapies and the role of consolidative non-invasive local ablative treatments (LATs) in these settings. The potential benefit of local treatment (LT) such as radiotherapy (RT) or surgery might be represented by an overall reduction of switching to subsequent systemic treatments lowering the risk of further systemic dissemination. Further randomized clinical trials will clarify the role of LT and their correct timing in relation to systemic targeted therapies.

1 June 2018 in Revue de Chirurgie Orthopédique et Traumatologique
Verified
Journal Article
Closed access
RCR. Casadei
R. Casadei
GDG. Drago
G. Drago
FPFrancesca Di Pressa
Francesca Di Pressa
DDD. Donati
D. Donati